Lesinurad
FDA-approved product (tablet, oral), marketed as Zurampic.
- Registered studies
- 22
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Gout
- Hyperuricemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Preparations increasing uric acid excretion
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
22registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lesinurad with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Open-Label Lesinurad Monotherapy Extension Study in Gout
NCT01650246 · start 2012-08
Registered record
- Registry ID
- NCT01650246
- Conditions
- Gout
- Interventions
- lesinurad
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-08
- Completion
- 2014-08
- Enrolment
- 143
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionlesinuradPhasePhase 3Registry statusCompletedLesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
NCT01508702 · start 2012-01
Registered record
- Registry ID
- NCT01508702
- Conditions
- Gout
- Interventions
- lesinurad; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2013-11
- Enrolment
- 214
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionlesinurad; PlaceboPhasePhase 3Registry statusCompletedCombining Lesinurad With Allopurinol in Inadequate Responders
NCT01510158 · start 2012-01
Registered record
- Registry ID
- NCT01510158
- Conditions
- Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Allopurinol; Allopurinol; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-08
- Enrolment
- 607
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionLesinurad; Lesinurad; Placebo; Allopurinol +2 morePhasePhase 3Registry statusCompletedCombination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
NCT01510769 · start 2012-01
Registered record
- Registry ID
- NCT01510769
- Conditions
- Tophaceous Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Febuxostat
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-06
- Enrolment
- 330
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTophaceous GoutInterventionLesinurad; Lesinurad; Placebo; FebuxostatPhasePhase 3Registry statusCompletedCombining Lesinurad With Allopurinol in Inadequate Responders
NCT01493531 · start 2011-12
Registered record
- Registry ID
- NCT01493531
- Conditions
- Gout
- Interventions
- Lesinurad; Lesinurad; Placebo; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2014-07
- Enrolment
- 610
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionLesinurad; Lesinurad; Placebo; AllopurinolPhasePhase 3Registry statusCompletedAllopurinol Combination Study
NCT01001338 · start 2009-10
Registered record
- Registry ID
- NCT01001338
- Conditions
- Gout
- Interventions
- RDEA594; Placebo; Allopurinol
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-10
- Completion
- 2016-08
- Enrolment
- 227
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGoutInterventionRDEA594; Placebo; AllopurinolPhasePhase 2Registry statusCompletedGout Dose Response Study
NCT00955981 · start 2009-07
Registered record
- Registry ID
- NCT00955981
- Conditions
- Hyperuricemia
- Interventions
- RDEA594; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-07
- Completion
- 2011-09
- Enrolment
- 123
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperuricemiaInterventionRDEA594; PlaceboPhasePhase 2Registry statusCompleted